JBIO · Insider Trading
Jade Biosciences, Inc. Common Stock
Every open-market purchase and sale reported by JBIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-26 | Mark Eisner | Director | A | +47,675 deriv. | — |
| 2026-06-11 | Christopher W. Cain | Director | A | +34,843 deriv. | — |
| 2026-06-11 | Lawrence Otto Klein | Director | A | +34,843 deriv. | — |
| 2026-06-11 | Erin Lavelle | Director | A | +34,843 deriv. | — |
| 2026-06-11 | Eric Dobmeier | Director | A | +34,843 deriv. | — |
| 2026-06-11 | Fairmount Funds Management LLC | Director | A | +174,215 deriv. | — |
| 2026-02-13 | Elizabeth Balta | See Remarks | A | +28,125 | — |
| 2026-02-13 | Andrew James King | See Remarks | A | +41,250 | — |
| 2026-02-13 | Tom Frohlich | Chief Executive Officer | A | +78,750 | — |
| 2026-02-13 | Bradford D. Dahms | Chief Financial Officer | A | +37,813 | — |
| 2025-10-08 | Fairmount Healthcare Co-Invest IV L.P. | Director | A | +6,665,630 | +$60.92M |
| 2025-07-14 | Bradford D. Dahms | Chief Financial Officer | A | +526,000 deriv. | — |
| 2025-05-19 | Tom Frohlich | Chief Executive Officer | Buy | +6,000 | +$44.40K |
| 2025-05-01 | Erin Lavelle | Director | A | +23,017 deriv. | — |
| 2025-05-01 | Eric Dobmeier | Director | A | +23,017 deriv. | — |
| 2025-05-01 | Lawrence Otto Klein | Director | A | +23,017 deriv. | — |
| 2025-05-01 | Christopher W. Cain | Director | A | +23,017 deriv. | — |
| 2025-05-01 | Peter Evan Harwin | Director | A | +92,068 deriv. | — |
| 2025-04-30 | Peter Kolchinsky | 10%+ Owner | J | +4,249,304 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Fairmount Healthcare Co-Invest IV L.P. | Director | 1,897,677 | $28.71M |
| Andrew James King | See Remarks | 386,113 | $5.84M |
| Tom Frohlich | Chief Executive Officer | 86,331 | $1.31M |
| Bradford D. Dahms | Chief Financial Officer | 37,813 | $572.11K |
| Peter Kolchinsky | 10%+ Owner | 28,206 | $426.76K |
| Elizabeth Balta | See Remarks | 28,125 | $425.53K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the JBIO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.